TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03210714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and/or biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT01977807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proscan, Zyoptix and Supracor
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proscan, Zyoptix and Supracor
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
Study: NCT03382262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Extended-release 32 mg FX006 IA injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAcs 40 mg
Description: Immediate-release 40mg TAcs IA injection
Study: NCT02578992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head-lift position
Description: A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7cm high pillow
Description: A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
Study: NCT01413828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent
Description: Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential
Description: Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Study: NCT03338036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Description: HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
Study: NCT02599857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONCOR smartphone application
Study: NCT03062267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Interventionist
Description: A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
Study: NCT02233582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study: NCT00903994

Intervention type: DRUG
Group type: OTHER
Intervention: Ketoprofen Topical Patch 20%
Description: Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
Study: NCT03105245

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)
Description: The intervention in this study is the time interval between anaesthetic administration and ECT stimulus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)
Description: The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
Study: NCT03384212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study: NCT02512588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTD-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03602144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
Study: NCT02340572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-080#022-DP
Description: hepcidin antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRS-080-Placebo#001
Description: Placebo treatment
Study: NCT02360449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Initiation Motivation Intervention
Description: The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
Study: NCT02157584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
Study: NCT03978572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Exercise intervention designed to improve muscular strength and power
Study: NCT03602144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
Study: NCT03978572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Continuous Cycling
Description: Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
Study: NCT04333797

Intervention type: OTHER
Group type: OTHER
Intervention: Risk and Protective Factors Assessment
Description: First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
Study: NCT04606030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioBridge® Collagen Matrix
Description: BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Study: NCT04552847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-octreotide
Description: One intravenous injection of 4 MBq/kg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
Study: NCT02547844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz + emtricitabina + tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilpivirina + emtricitabina + tenofovir
Study: NCT04991415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Study: NCT01119417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Low dose day: 25 nmol/min, single IV infusion for 15 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Low dose day: 50 nmol/min, single IV infusion for 15 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bq123
Description: High dose day: 100 nmol/min, single IV infusion for 15 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: High dose day: 300 nmol/min, single IV infusion for 15 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2-3 IV saline infusions for 15 min each.
Study: NCT00492583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (BB-12)
Description: The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
Study: NCT03978572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Cycling
Description: Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
Study: NCT01424319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan low dose group
Description: Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan high dose group
Description: Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atrasentan placebo group
Description: Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
Study: NCT00492583

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
Study: NCT03430336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDSS provides drug-therapy relevant information
Description: External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of medication
Description: GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
Study: NCT01833013

Intervention type: OTHER
Group type: OTHER
Intervention: live birth date and quality of life assessment
Study: NCT02071121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: BIIB061 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: BIIB061 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: BIIB061 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: BIIB061 capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: BIIB061 capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BIIB061 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-BIIB061
Description: Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
Study: NCT01161862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal (insulin and glucagon) artificial pancreas
Description: Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal (insulin and glucagon) artificial pancreas
Description: Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
Study: NCT04100265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)
Description: The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)
Description: The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
Study: NCT01175252

Intervention type: OTHER
Intervention: Database analysis
Description: Review and collect data from database
Study: NCT03598556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 180,000IU Vitamin D3 oral emulsion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04073498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
Study: NCT03430336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of medication appropriateness
Description: GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication plan
Description: GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance in medication process
Description: GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
Study: NCT04379960

Intervention type: OTHER
Intervention: Peptides
Description: Peptides will be added to PBMCs in in vitro cell culture.

Intervention type: OTHER
Intervention: Peptides
Description: Peptides will be added to PBMCs in in vitro cell culture.
Study: NCT00360672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
Study: NCT00669513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation
Description: Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
Study: NCT04333992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol and remifentanil
Description: intravenous propofol and remifentanil using target-controlled infusion (TCI) devices

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane and remifentanil
Description: inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
Study: NCT03938636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT02955771

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PDT-Deuteporfin（6 hour)
Description: Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PDT-Deuteporfin（9 hour)
Description: Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenting
Description: The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenting
Description: The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).

Intervention type: DEVICE
Group type: OTHER
Intervention: stenting
Description: The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
Study: NCT04073498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
Study: NCT00068484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT03216070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 MG
Description: 50mg of dasatinib orally daily